Blood: A new neuroamide analogue and mechanism that can effectively inhibit invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating in
-
Last Update: 2020-06-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Primary oozed lymphoma (PEL) is an invasive malignant tumor with poor prognosis even in the case of active chemotherapy, usually accompanied by Kaposi sarcoma-associated herpes virus (Kaposi's sarcoma-associated herpesvirus, KSHV) infection, one of the human cancer-causing virusesAt present, THERE IS NO SPECIFIC TREATMENT FOR PEL, SO IT IS IMPORTANT TO DEVELOP NEW TREATMENTSLipid metabolism plays an important role in determining the fate of tumor cellsPrevious studies have shown that phospholipid metabolism is associated with the survival of KSHV plus tumor cellsIn order to further develop the targeted treatment of phospholipid metabolism, after screening a series of newly synthesized neuroamide analogues, Chen et alscreened out compounds with effective anti-PEL activityThese compounds induce the production of PEL apoptosis, cell cycle block and intracellular ceramide by regulating ceramide synthesis or ceramide metabolism enzymes, and significantly inhibit tumor progression in the body without significant toxicityThese new compounds also increase the expression of the virus lysate gene in PEL cellsIn addition, transcription alcdc analysis also revealed the mechanism of these compounds to induce pel cell death, and identified a new set of cell genes, including AURKA and CDCA3, subject to the regulation of lipid metabolism, is essential for PEL survivalThese data provide a framework for the development of targeted drugs based on phospholipid metabolism in this viral-related malignant tumor
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.